PharmaShots

05

Shots: The US FDA has accepted NDA of oral Wegovy for chronic weight management & major adverse CV events risk reduction in adults with obesity or overweight & comorbidities (PDUFA:…

13

16 hours ago

INSIGHTS+

The US FDA New Drug Approvals in April 2025

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2025 The US FDA has approved a total of 3 new drug including 1 new…

13

17 hours ago

Video

LIFE SCIENCES | DAILY NEWS | MAY 13, 2025 | PHARMASHOTS

13

17 hours ago

News

Mentice Reports US Launch of Ankyras 4.0 to Advance Patient-Specific Aneurysm Planning for Neuro Interventions

Shots: Following FDA 510(k) clearance, Mentice has launched Ankyras 4.0 for pts-specific flow diverter planning to treat intracranial aneurysms in the US Ankyras 4.0 introduces DICOM node integration, a redesigned…

13

18 hours ago

News

Spice Biotechnologies Partners with AbTherx to Discover Antibodies in Immuno-Oncology

Shots: AbTherx has entered into a multi-program antibody discovery partnership with Spice Biotechnologies to identify antibodies against targets selected by Spice Bio, using AbTherx’s Atlas Mouse technologies As per the…

13

19 hours ago

News

QIAGEN to Acquire Genoox for ~$80M

Shots: QIAGEN has entered into a definitive agreement to acquire Genoox, a provider of AI-driven software that allows clinical laboratories to scale & accelerate the analysis of complex genetic tests…

13

21 hours ago

News

Genentech Reports P-III (APHINITY) Trial Data of Perjeta Regimen for Early-Stage Breast Cancer

Shots: Genentech has reported 10yr. P-III (APHINITY) trial data assessing Perjeta + Herceptin & CT vs Herceptin + CT vs PBO as an adj. therapy in 4804 pts with operable…

13

22 hours ago

News

MavriX Bio Reports the US FDA’s IND Clearance of MVX-220 for Angelman Syndrome

Shots: The US FDA has approved IND application of MVX-220 for the treatment of Angelman Syndrome (AS) to initiate P-I/II (ASCEND-AS) trial, with first pts dosing expected in H2’25 The P-I/II…

13

23 hours ago

News

UK’s MHRA Approves AstraZeneca’s Trixeo Aerosphere with Near-Zero GWP Propellant for Chronic Obstructive Pulmonary Disease (COPD)

Shots: The UK’s MHRA has approved Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) with HFO-1234ze(E), a next-generation, near-zero global warming potential (GWP) propellant for treating COPD in adults; regulatory review is…

12

2 days ago

SPOTLIGHT

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots

In the CXO Talks podcast, PharmaShots engaged in a riveting dialogue exchange with Colin Banas, Chief Medical Officer at DrFirst. Colin highlights the evolution of DrFirst from becoming a leader…

12

2 days ago

THOUGHTSPOT

Innovative orthodontic solutions revolutionizing patient care and treatment results

The field of orthodontics is undergoing a significant transformation, driven by cutting-edge technologies and patient-centric approaches. Innovations in this area are not only enhancing treatment outcomes but also revolutionizing the…

Novo Nordisk Reports the US FDA’s NDA Acceptance of Oral Wegovy for Weight Management

The US FDA New Drug Approvals in April 2025

LIFE SCIENCES | DAILY NEWS | MAY 13, 2025 | PHARMASHOTS

Mentice Reports US Launch of Ankyras 4.0 to Advance Patient-Specific Aneurysm Planning for Neuro Interventions

Spice Biotechnologies Partners with AbTherx to Discover Antibodies in Immuno-Oncology

QIAGEN to Acquire Genoox for ~$80M

Genentech Reports P-III (APHINITY) Trial Data of Perjeta Regimen for Early-Stage Breast Cancer

MavriX Bio Reports the US FDA’s IND Clearance of MVX-220 for Angelman Syndrome

UK’s MHRA Approves AstraZeneca’s Trixeo Aerosphere with Near-Zero GWP Propellant for Chronic Obstructive Pulmonary Disease (COPD)

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots

Innovative orthodontic solutions revolutionizing patient care and treatment results

Contact US

FOLLW US

FOLLW US

Sign Up to Our Newsletter